Exelixis Closes Pennsylvania Site, Cuts 130 Jobs in Major Restructuring

Exelixis is closing its King of Prussia, Pennsylvania site and laying off 130 employees as part of a company-wide reorganization134.

The decision comes after the company expanded its workforce during the pandemic and post-pandemic periods, including hiring for many fully remote positions1.

Exelixis is consolidating operations at its Alameda, California headquarters, hoping to relocate some affected roles there1.

The move follows recent positive clinical trial results for zanzalintinib, which is positioned as a potential successor to Cabometyx (cabozantinib), the company's flagship cancer drug14.

The restructuring is aimed at improving coordination and maximizing opportunities for Exelixis’ oncology drug pipeline1.

The layoffs at the Pennsylvania site and focus on Alameda align with broader cost-cutting and operational efficiency trends seen in the biotech industry in 20254.

Sources:

1. https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing

3. https://firstwordpharma.com/story/5992696

4. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025